Agenda of the ACIP Meeting - June 29-30, 2005

CENTERS FOR DISEASE CONTROL AND PREVENTION (Final 6-27-05) ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES MARRIOTT CENTURY CENTER HOTEL ATLANTA, GEORGIA JUNE 29-30, 2005

AGENDA ITEM PURPOSE/ACTION PRESIDER/PRESENTER(s) June 29 8:00 Welcome Dr. M. Levin (Chair, ACIP) Dr. L. Pickering (CDC, OD)

8:30 Tdap Adolescent Recommendation Pertussis Working Group Update Information Dr. J. Abramson (ACIP) Adolescent Pertussis and Tdap Information Dr. M. Cortese (NIP) Tetanus and diphtheria containing vaccines Information Dr. T. Murphy (NIP) Safety monitoring Information Dr. J. Iskander (OD) Supply, planned studies Information TBD (GSK, Sanofi Pasteur) Use of Tdap among adolescents 11-18 years Decision Dr. K. Broder (NIP) VFC Vote Dr. G. Wallace (NIP)

10:30 BREAK

11:00 Hepatitis B Vaccine Recommendation Information Dr. E. Mast (NCID) Childhood recommendations Discussion Decision

12:30 LUNCH

1:30 Recommendations for Use of Hepatitis A Information Dr. B. Bell (NCID) Discussion Dr. G. Armstrong (NCID)

2:30 MMRV Working Group/Introduction Information Dr. J. Campbell (ACIP) Overview of Varicella Epidemiology Dr. D. Guris (NIP) Physician survey results Dr. Marin (NIP)

3:30 BREAK

4:00 Update cost-effectiveness analysis Dr. F. Zhou (NIP) Summary of AAP recommendations Dr. C. Meissner (Tufts)

Votes Routine 2nd dose vaccination at 4-6 yrs of age Discussion & Vote Dr. J. Seward (NIP) Catch-up vaccination with 2nd dose of children Discussion & Vote 7-12 yrs of age who have only rec’d 1 dose School-entry requirements for middle and high Discussion & Vote schools and colleges Vaccination of susceptible persons > years of Discussion & Vote age Routine screening of pregnant women & post- Discussion & Vote partum vaccination of susceptible women Expanding recommendation on vaccination of Discussion & Vote HIV (+) children Note: * These votes will be taken only if appropriate in light of prior decisions by or ACIP. Second dose varicella *Discussion & Vote (VFC) Dr. G. Wallace (NIP)

5:30 General Recommendations Work Group : Information Dr. A. Kroger (NIP) Vaccine storage and handling

6:15 Revised Adult Immunization Schedule Information Dr. R. Strikas (NIP) Decision

6:30 Public Comment

6:45 ADJOURN

AGENDA ITEM PURPOSE/ACTION PRESIDER/PRESENTER(s) June 30 8:00 Unfinished Business

8:30 Disease burden and epidemiology Information TBD zoster vaccine trial results Zoster vaccine clinical trial results Information Dr. P. Annunziato (Merck) Discussion

9:15 Tdap – Use in Adults Epidemiology of pertussis in adults Information Dr. K. Kretsinger (NIP) Potential strategies using Tdap – Overview Discussion Dr. T. Murphy (NIP)

10:15 BREAK

10:45 Human Papilloma VirusWorkgroup Overview Information Dr. L. Markowitz (NCHSTP) HPV natural history Dr. B. Unger (NCID) Cervical cancer epidemiology, Pap screening and burden of disease Dr. H. Lawson (NCCDPHP) HPV vaccine cost-effectiveness Dr. S. Goldie (Harvard)

12:30 LUNCH

1:30 ACIP/NVAC Joint Working Group: Information Dr. C. Bridges (NIP) Preliminary results on pandemic vaccine Discussion prioritization

2:15 ACIP/HICPAC joint statement on Discussion Dr. M. Pearson (HICPAC/NCID) immunization of health care workers Decision against influenza

2:30 The effectiveness of an investigational Information Dr. P. Heaton (Merck) pentavalent (Human-Bovine) reassortant rotavirus vaccine (PRV) to reduce health care utilization for rotavirus gastroenteritis

Issues concerning the rotateq vaccine Information Dr. U. Parashar (NIP) Note: * These votes will be taken only if appropriate in light of prior decisions by or ACIP. 3:00 HIV Vaccine Working Group Update Information Dr. G. Birkhead (ACIP) Discussion

3:10 Updates: Ex-officios and CDC

3:20 Public Comment

3:35 ADJOURN

Note: * These votes will be taken only if appropriate in light of prior decisions by or ACIP.